Comparison of the Time to Recurrence Between Ranibizumab and Aflibercept

N/AUnknownNCT02126904

Yokohama City University Medical Center200 enrolled

Overview

The investigators compared the time to recurrence after ranibizumab or aflibercept loading in patients with AMD.

Study Type

OBSERVATIONAL

Enrollment

200

Conditions

The Injection Burden

Interventions

IVA groupDRUG

Eligibility

Sex: ALLMin age: 50 Years

Medical Language ↔ Plain English

Inclusion Criteria: * They must have had BCVA better than 20/400 and had three consecutive induction treatment of ranibizumab or aflibercept. Exclusion Criteria: * patients with eye diseases that could potentially influence the visual acuity of the studied eye, such as glaucoma, macular hole, diabetic retinopathy, or rhegmatogenous retinal detachment.

Locations (1)

Yokohama City University Medical Center

Yokohama, Kanagawa, Japan

RECRUITING

Outcomes

Primary Outcomes

Time to recurrence after induction phase

Time frame depends on patients because recurrence time is different.

Time frame: More than 3 months from baseline

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.